Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 2/20 | 0.57 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.56 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.56 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.53 |
| ▸ | AR | P10275 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyroquilon SCHEMBL8820252 | 0.88 | MAP2K1 (0.55) | CYP11B1CYP11B2MAP2K1 | |
| Pyroquilon SCHEMBL29473240 | 0.88 | MAP2K1 (0.55) | CYP11B1CYP11B2MAP2K1 | |
| Pyroquilon SCHEMBL22234 | 0.88 | MAP2K1 (0.55) | CYP11B1CYP11B2MAP2K1 | |
| SCHEMBL988203 | 0.87 | CES1 (0.56) | CES1CYP11B1CYP11B2 | |
| Pyroquilon SCHEMBL29473172 | 0.86 | MAP2K1 (0.54) | CYP11B1CYP11B2MAP2K1 | |
| Pyroquilon SCHEMBL19409911 | 0.86 | MAP2K1 (0.54) | CYP11B1CYP11B2MAP2K1 | |
| Pyroquilon SCHEMBL29473299 | 0.85 | MAP2K1 (0.53) | CYP11B1CYP11B2MAP2K1 | |
| Pyroquilon SCHEMBL29473298 | 0.85 | MAP2K1 (0.53) | CYP11B1CYP11B2MAP2K1 | |
| SCHEMBL7247820 | 0.85 | CES1 (0.49) | CES1CYP11B1CYP11B2MAP2K1 | |
| SCHEMBL31649829 | 0.85 | CES1 (0.49) | CES1CYP11B1CYP11B2MAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102404-A1 | THYROID STIMULATING HORMONE RECEPTOR (TSHR) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2026-04-16 | — | — | US | disclosed |
| EP-3372600-B1 | FUSED HETEROCYCLIC COMPOUND DERIVATIVE AND APPLICATION THEREOF | NHWA PHARMA CORP (CN) | 2021-09-08 | — | — | EP | disclosed |
| EP-3239147-A1 | QUINOLINE DERIVATIVE | Ono Pharmaceutical Co., Ltd. (JP) | 2017-11-01 | — | — | EP | disclosed |
| WO-2017071576-A1 | FUSED HETEROCYCLIC COMPOUND DERIVATIVE AND APPLICATION THEREOF | 江苏恩华药业股份有限公司 | 2017-05-04 | — | — | WO | disclosed |
| US-20140187784-A1 | RADIOACTIVE QUINOLINONE DERIVATIVE AND PHARMACEUTICAL DRUG COMPRISING THE SAME | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2014-07-03 | — | — | US | disclosed |
| EP-2749561-A1 | Radioactive quinolinone derivative and pharmaceutical drug comprising the same | Kyoto University (JP) | 2014-07-02 | — | — | EP | disclosed |
| US-8541404-B2 | Inhibitors of the human aldosterone synthase CYP11B2 | ELEXOPHARM GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| EP-2280954-B1 | 6-PYRIDIN-3-YL-3,4-DIHYDRO-1H-QUINOLIN-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HUMAN ALDOSTERONE SYNTHASE CYP11B2 | UNIV SAARLAND (DE) | 2013-03-27 | — | — | EP | disclosed |
| US-20110118241-A1 | 6-Pyridin-3-YL-3,4-Dihydro-1H-Quinolin-2-One Derivatives and Related Compounds as Inhibitors of the Human Aldosterone Synthase CYP11B2 | UNIVERSITAT DES SAARLANDES (DE) | 2011-05-19 | — | — | US | disclosed |
| US-20110112067-A1 | Inhibitors of the Human Aldosterone Sythase CYP11B2 | UNIVERSITAT DES SAARLANDES (DE) | 2011-05-12 | — | — | US | disclosed |
| US-7462628-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-09 | — | — | US | disclosed |
| US-20070021391-A1 | Preventive/remedy for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-25 | — | — | US | disclosed |
| US-20070021391-A1 | Preventive/remedy for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-25 | — | — | US | disclosed |
| US-7138533-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-21 | — | — | US | disclosed |
| US-7132547-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-07 | — | — | US | disclosed |
| US-20060211675-A1 | Preventives/remedies for urinary disturbance | ISHIHARA YUJI | 2006-09-21 | — | — | US | disclosed |
| US-20060063769-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-03-23 | — | — | US | disclosed |
| US-20050197362-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-09-08 | — | — | US | disclosed |
| EP-1466625-A1 | PREVENTIVES/REMEDIES FOR URINARY DISTURBANCE | Takeda Chemical Industries, Ltd. (JP) | 2004-10-13 | — | — | EP | disclosed |
| US-20040138230-A1 | Heterocyclic substituted piperazines for the treatment of schizophrenia | ANDREANA TONJA LYNN (US) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138230-A1 | Heterocyclic substituted piperazines for the treatment of schizophrenia | CNR1, DRD2, CNR2 | CES1 2134/4885CYP11B1 1271/4885CYP11B2 1195/4885 |
| US-20140187784-A1 | RADIOACTIVE QUINOLINONE DERIVATIVE AND PHARMACEUTICAL DRUG COMPRISING THE SAME | CYP11B2, CYP11B1, HSD11B1 | CES1 187/4885CYP11B1 2/4885CYP11B2 1/4885 |
| US-20070021391-A1 | Preventive/remedy for urinary disturbance | ACHE, BCHE, CHAT | CES1 109/4885CYP11B1 1322/4885CYP11B2 1334/4885 |
| US-20060063769-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, CHRM1 | CES1 310/4885CYP11B1 615/4885CYP11B2 872/4885 |
| US-20260102404-A1 | THYROID STIMULATING HORMONE RECEPTOR (TSHR) ANTAGONISTS AND USES THEREOF | TSHR, TRHR, THRB | CES1 582/4885CYP11B1 342/4885CYP11B2 365/4885 |
| US-20110118241-A1 | 6-Pyridin-3-YL-3,4-Dihydro-1H-Quinolin-2-One Derivatives and Related Compounds as Inhibitors of the Human Aldosterone Synthase CYP11B2 | HSD11B1, HSD11B2, CYP4A11 | CES1 113/4885CYP11B1 6/4885CYP11B2 4/4885 |
| US-20050197362-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, CHRM1 | CES1 310/4885CYP11B1 615/4885CYP11B2 872/4885 |
| US-20110112067-A1 | Inhibitors of the Human Aldosterone Sythase CYP11B2 | HSD11B1, HSD11B2, CYP11B1 | CES1 63/4885CYP11B1 3/4885CYP11B2 4/4885 |
| US-20060211675-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, ACE | CES1 982/4885CYP11B1 698/4885CYP11B2 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.